Alogliptin Enhances Implant Osseointegration in Diabetes Through an Osteogenic–Angiogenic Immunomodulatory Procedure
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27156800 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Xiangdong Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Air Force Medical University, Xi'an 710032, China. Hauptthemen laut MEDLINE: Osteogenesis, Osseointegration, Diabetes Mellitus, Experimental, Piperidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shaanxi Science and Technology Department, Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences, the key research and development program of Shaanxi.
Themen: Diabetes mellitus
Abstract (Originalsprache)
People with diabetes often have a high rate of oral implant failure and unstable long-term treatment effects. It is urgent to find the potential mechanisms and effective cure methods to address the increasing demand for dental restoration in recent years. This paper aims to find an influential factor, and a probable treatment resulting from it, to improve poor osseointegration and achieve favorable bone regeneration. To find out the influential factor of poor diabetic osseointegration, we compared marginal bone loss among patients taking different hypoglycemic drugs. To verify our pre-clinical findings, we performed in vitro experiments as well as micro-CT, fluorescence intensity, and histopathological analysis methods after establishing a diabetic rat model controlled by different systemic hypoglycemic drugs. To enhance implant osseointegration and find out the underlying mechanism, we proposed the GelMA–alogliptin hydrogel system and tested the scratch wound healing, cell adhesion, CCK-8, live-dead cell staining, osteogenesis, qPCR, and Western blot methods based on diabetic rat-derived BMSCs, HUVECs and BMMS, as well as the in vivo experiments in diabetic rats. People with diabetes under DPP4i (alogliptin) exhibit the lowest marginal bone loss. The systemic alogliptin and locally delivered peri-implant GelMA–alogliptin hydrogel treatment promoted bone regeneration around diabetic implants, enhanced diabetic-derived BMSC activity and migration through GLP1R/GSK3β/β-catenin and induced osteogenic differentiation, and promoted vascular regeneration and inflammation control. Alogliptin has positive effects on the oral implant health of people with diabetes. A locally delivered GelMA–alogliptin hydrogel system exhibits competitive ability to improve diabetic bone microenvironment and enhance implant osseointegration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, Air Force Medical University, Xi'an 710032, China.
- State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial…
- State Key Laboratory of Military Stomatology and National Clinical Research Center for Oral Diseases and Shaanxi Engineering Research Center for Dental Materials and Advanced Manufacture, Department of Oral Implants, Sc…
ORCID-Profile: Xiangdong Liu, Mingkai Li
Förderung
- Shaanxi Science and Technology Department
- Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
- the key research and development program of Shaanxi
- Key Research and Development Program
- Non-profit Central Research Institute Fund
- Shaanxi Health Scientific Research Innovation Team for Comprehensive Treatment of Complex Facial Injuries
Zitieren
APA
Liu, X., Chen, Z., Yang, L., Ma, W., Liu, Y., Song, Y., Ding, M., Tian, L., & Li, M. (2026). Alogliptin Enhances Implant Osseointegration in Diabetes Through an Osteogenic–Angiogenic Immunomodulatory Procedure. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27156800
Vancouver
Liu X, Chen Z, Yang L, Ma W, Liu Y, Song Y, et al. Alogliptin Enhances Implant Osseointegration in Diabetes Through an Osteogenic–Angiogenic Immunomodulatory Procedure. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27156800
BibTeX
@article{Liu2026,
author = {Liu, Xiangdong and Chen, Zijun and Yang, Liu and Ma, Wei and Liu, Yiwen and Song, Yingliang and Ding, Mingchao and Tian, Lei and Li, Mingkai},
title = {Alogliptin Enhances Implant Osseointegration in Diabetes Through an Osteogenic–Angiogenic Immunomodulatory Procedure},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27156800}
}
EUVIMED